The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy.
نویسندگان
چکیده
It is currently being debated whether pharmacokinetic monitoring of mycophenolic acid (MPA), the active constituent of mycophenolate mofetil (MMF), can optimize MMF therapy after organ transplantation. This open-label longitudinal study in pediatric renal transplant recipients was designed to investigate the pharmacokinetic (PK)/pharmacodynamic relationship of total and free MPA and to establish PK values for the assessment of an individual's MPA PK parameters. Fifty-four children, aged 2.2 to 17.8 yr, on an immunosuppressive triple regimen consisting of cyclosporin A, prednisone, and MMF (600 mg/m(2) body surface area twice daily) were investigated 1 wk and 3 wk (initial phase) and 3 mo and 6 mo (stable phase) after renal transplantation. MPA was measured by reverse phase HPLC, free MPA by HPLC after separation by ultrafiltration. There was an association between the risk of acute rejection episodes and MPA-AUC(0-12) values or MPA predose levels; by receiver operating characteristic analysis, an AUC(0-12) of 33.8 mg x h/L in the initial phase posttransplant had a diagnostic sensitivity of 75% and a diagnostic specificity of 64% for discrimination of patients with acute rejections. The respective discrimination threshold for the MPA predose concentration was 1.2 mg/L with a sensitivity of 83% and a specificity of 64%. In contrast, high free, but not total, MPA-AUC(0-12) values were associated with an increased risk of the MMF-related side effects leukopenia and/or infections. These data indicate that therapeutic drug monitoring of MPA has the potential for optimization of MMF efficacy in this patient population by steering patients away from the low values of MPA PK variables that are associated with an increased rejection risk. For the assessment of the toxic risk of MMF regarding leukopenia and/or infections, measurement of free MPA appears to be more appropriate.
منابع مشابه
Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy.
BACKGROUND HPLC is currently the preferred method for accurate measurement of mycophenolic acid (MPA). This study was designed to validate the Emit compared with HPLC in relation to clinical outcome measurements. METHODS Pediatric renal-transplant recipients (n = 50) on an immunosuppressive triple regimen consisting of cyclosporin A, prednisone, and mycophenolate mofetil (600 mg/m(2) twice pe...
متن کاملPopulation pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches.
Mycophenolic acid (MPA) is an immunosuppressive drug widely used in the prevention of acute rejection in pediatric renal transplant recipients and is characterized by a wide inter-individual variability in its pharmacokinetics. The aim of this study was to compare population pharmacokinetic modeling of MPA in pediatric renal transplant recipients given mycophenolate mofetil, the ester prodrug o...
متن کاملEffect of Ganciclovir on Pharmacokinetics of Mycophenolic Mofetil, in Kidney Transplant Patients
ObjectiveMycophenolate mofetil (MMF) is commonly administered concomitantly with ganciclovir for managingtransplant recipients who infected with CMV. This study was conducted to evaluate the probable effects ofganciclovir on Mycophenolic acid (MPA) pharmacokinetic.Materials and MethodsTen kidney transplant recipients who full field inclusion and exclusion criterias enrolled in this study. Thefi...
متن کاملPharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients.
BACKGROUND AND OBJECTIVES The introduction of mycophenolate mofetil has improved graft survival after organ transplantation; however, its use may be limited by important adverse effects. For overcoming these problems, an enteric-coated formulation of mycophenolate sodium has been developed, but pharmacokinetic data of mycophenolic acid release from this formulation are scanty. DESIGN, SETTING...
متن کاملPharmacokinetics of mycophenolic acid (MPA) and free MPA in paediatric renal transplant recipients--a multicentre study. The German Study Group on Mycophenolate Mofetil (MMF) Therapy.
s 34 transplant, pharmacokinetic data for MPA in this time. This discrepancy can be attributed to a 35% decline (P<0.01) of the free MPA fraction from 1.4% patient population are scarce and dosage guidelines are therefore preliminary. (range 0.6–5.1%) in the initial phase post-transplant to 0.9% (range 0.5–1.9%) in the stable phase. The decrease of the free MPA fraction is probably caused Metho...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Journal of the American Society of Nephrology : JASN
دوره 13 3 شماره
صفحات -
تاریخ انتشار 2002